Lupin partners with Takeda to commercialise Vonoprazan
The drug will be marketed under the brand name Lupin’s Lupivon and will be available in two strengths - 10 mg and 20 mg
Author
Eugia Steriles receives EIR from US FDA
The inspection was conducted between March 28, 2024 to April 05, 2024
Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030
GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by…
Neovantage Innovation Parks secures a green loan for its life sciences real estate portfolio
The Neovantage Innovation Parks portfolio is set up as a joint venture (JV) between Ivanhoé Cambridge, the real estate group of…
Novo Nordisk GBS launches safe pharmaceuticals disposal initiative for employees
Launched internally for employees, this eco-pharmacovigilance initiative is designed to minimise environmental impact and enhance…
Manufacturing the right talent
As pharma manufacturing evolves to meet dynamic market demands, regulatory shifts and technological advancements,Kavita Jani…
Strides Pharma subsidiary receives USFDA approval for 60 mg Fluoxetine tablets
Strides Pharma Global secures approval for Fluoxetine Tablets, completing its portfolio for the US market
US FDA approves Eli Lilly’s drug for eczema
Eli Lilly’s Ebglyss, a new eczema treatment, gains US FDA approval for patients 12 and older, offering a monthly dosing option and…
Passing of Biosecure Act a positive development
Jonathan Hunt MD and CEO, Syngene International analyses that though the change in the Biosecure Act around the timeline of…
Continuous manufacturing: Changing the paradigm in the pharmaceutical manufacturing sector
The author explains how continuous manufacturing is reshaping pharmaceutical production